Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone.
J Radiosurg SBRT
; 5(4): 277-283, 2018.
Article
en En
| MEDLINE
| ID: mdl-30538888
ABSTRACT
PURPOSE/OBJECTIVES:
Stereotactic radiosurgery (SRS) is used as a treatment option for breast cancer brain metastases. It is unclear what factors predict neurologic death for these patients. MATERIALS/METHODS:
A total of 128 patients with breast cancer brain metastases were treated with upfront SRS alone in this study. Survival was estimated using the Kaplan-Meier method. Clinicopathologic factors evaluated included age, ER/PR status, Her2 status, numbers of brain metastases treated, minimum SRS dose, disease-specific GPA, extracranial disease status and systemic disease burden.RESULTS:
ER or PR positivity was associated with a trend towards decreased neurologic death (subdistribution hazard ratio (sHR) = 0.54, p=0.06). Factors associated with non-neurologic death include extracranial disease status (sHR = 2.02, p=0.02) and dose (sHR = 1.11, p=0.02); Her2-positivity was associated with reduced hazard of non-neurologic death (sHR 0.52, p=0.05).CONCLUSIONS:
ER/PR positivity was associated with a trend towards less neurologic death. HER2 positivity was associated with a trend towards less non-neurologic death.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
6_brain_nervous_system_cancer
/
6_breast_cancer
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
J Radiosurg SBRT
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos